Trial site
The Third People's Hospital of Zhengzhou
Zhengzhou, Henan 450000, ChinaNot linked to an institution yet
The trials here
What the 10 trials at this site are about, from their registry records.
- Phase
- Phase 24 trials
- Phase 33 trials
- Phase 1/22 trials
- Phase 41 trial
- Status
- Not yet recruiting5 trials
- Recruiting4 trials
- Active, not recruiting1 trial
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.3 trials
- Innovent Biologics (Suzhou) Co. Ltd.2 trials
- Binhui Biopharmaceutical Co., Ltd.1 trial
- MindRank AI Ltd1 trial
- Shanghai Pharmaceuticals Holding Co., Ltd1 trial
- and 2 more
Running trials
Recruiting
A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
NCT07653685· Phase 1/2· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Contact: HaiCun Wang, Master
Not yet recruiting
A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE)
NCT07274137· Phase 3· MindRank AI Ltd· Source
Contact: Junpei Chang
Recruiting
A Phase II Trial of LM103 in Advanced Melanoma
NCT07310784· Phase 2· Suzhou BlueHorse Therapeutics Co., Ltd.· Source
Contact: Xianbin Liang
Recruiting
Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
NCT07110415· Phase 4· SPH Qingdao Growful Pharmacetical Co.,Ltd· Source
Contact: Bai dong yang
Recruiting
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
NCT07003074· Phase 3· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Contact: Lige Yao, Master
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
NCT06797297· Phase 2· Innovent Biologics (Suzhou) Co. Ltd.· Source
Recruiting
The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
NCT06452706· Phase 2· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Contact: Lige Yao, Doctor
Recruiting
A Clinical Study of T3011 in Subjects With Advanced Melanoma
NCT06214156· Phase 1/2· Shanghai Pharmaceuticals Holding Co., Ltd· Source
Contact: Xianbin Liang
Recruiting
A Study of IBI363 in Subjects With Advanced Melanoma
NCT06081920· Phase 2· Innovent Biologics (Suzhou) Co. Ltd.· Source
Contact: Xianbin Liang
Recruiting
OH2 Injection in Melanoma
NCT05868707· Phase 3· Binhui Biopharmaceutical Co., Ltd.· Source
Contact: Wentao Xu
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error